Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry - PubMed (original) (raw)

doi: 10.3324/haematol.12234. Epub 2008 Mar 5.

Affiliations

• PMID: 18322251
• DOI: 10.3324/haematol.12234

Free article

Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry

Philip S Rosenberg et al. Haematologica. 2008 Apr.

Free article

Abstract

Background: Fanconi anemia is an inherited genomic instability syndrome associated with progressive bone marrow failure leading to death or the requirement for hematopoietic stem cell transplantation, acute myeloid leukemia, and solid tumors. Prior epidemiological studies have quantified the risks of bone marrow failure, acute myeloid leukemia and solid tumors, but these estimates have not been replicated.

Design and methods: We assembled a cohort of 181 patients with Fanconi anemia mostly from Germany. We calculated the ratio of observed to expected cancers, and the risks of bone marrow failure, acute myeloid leukemia, and solid tumors by age.

Results: The first adverse event was bone marrow failure in 66 patients, acute meyloid leukemia in 14 patients and solid tumors in 10 patients. The ratio of observed to expected cancers was 44 for all cancers, 26 for all solid tumors, and 868 for acute myeloid leukemia; these increased risks were statistically significant. Significantly elevated ratios of observed to expected cancers were observed for esophageal (6281), vulvar (2411), head and neck (240), breast (34) and brain (23) tumors. Absent or abnormal radii, and a five-item congenital abnormality score, were significant risk factors for bone marrow failure. The cumulative incidence of bone marrow failure by the age of 10 years varied from 12.6% in the lowest bone marrow failure risk group to 84% in the highest. The relative hazard of bone marrow failure was significantly higher in complementation group G versus A (relative hazard=2.2) and in C versus A (relative hazard=5.4).

Conclusions: Findings from the German Fanconi Anemia Registry cohort validate prior risk estimates, and strongly support the concept that Fanconi anemia is a highly penetrant cancer susceptibility syndrome with early onset of acute myeloid leukemia and slightly later onset of specific solid tumors.

PubMed Disclaimer

Comment in

• Fanconi anemia is a highly penetrant cancer susceptibility syndrome.
  Dokal I. Dokal I. Haematologica. 2008 Apr;93(4):486-8. Haematologica. 2008. PMID: 18379006 No abstract available.

Similar articles

• Fanconi anemia is a highly penetrant cancer susceptibility syndrome.
  Dokal I. Dokal I. Haematologica. 2008 Apr;93(4):486-8. Haematologica. 2008. PMID: 18379006 No abstract available.
• Cancer incidence in persons with Fanconi anemia.
  Rosenberg PS, Greene MH, Alter BP. Rosenberg PS, et al. Blood. 2003 Feb 1;101(3):822-6. doi: 10.1182/blood-2002-05-1498. Epub 2002 Sep 5. Blood. 2003. PMID: 12393424
• Fanconi anemia and the development of leukemia.
  Alter BP. Alter BP. Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):214-21. doi: 10.1016/j.beha.2014.10.002. Epub 2014 Oct 15. Best Pract Res Clin Haematol. 2014. PMID: 25455269 Free PMC article. Review.
• Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry.
  Tamary H, Nishri D, Yacobovich J, Zilber R, Dgany O, Krasnov T, Aviner S, Stepensky P, Ravel-Vilk S, Bitan M, Kaplinsky C, Ben Barak A, Elhasid R, Kapelusnik J, Koren A, Levin C, Attias D, Laor R, Yaniv I, Rosenberg PS, Alter BP. Tamary H, et al. Haematologica. 2010 Aug;95(8):1300-7. doi: 10.3324/haematol.2009.018119. Epub 2010 Apr 30. Haematologica. 2010. PMID: 20435624 Free PMC article.
• Current clinical management of Fanconi anemia.
  Smith AR, Wagner JE. Smith AR, et al. Expert Rev Hematol. 2012 Oct;5(5):513-22. doi: 10.1586/ehm.12.48. Expert Rev Hematol. 2012. PMID: 23146055 Review.

Cited by

• Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.
  Rai SK, Du W, Zhang J, Yu H, Deng Y, Fei P. Rai SK, et al. Front Med (Lausanne). 2024 Oct 3;11:1462810. doi: 10.3389/fmed.2024.1462810. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39421870 Free PMC article.
• In Fanconi anemia, impaired accumulation of bone marrow neutrophils during emergency granulopoiesis induces hematopoietic stem cell stress.
  Hu L, Huang W, Liu B, Eklund EA. Hu L, et al. J Biol Chem. 2024 Aug;300(8):107548. doi: 10.1016/j.jbc.2024.107548. Epub 2024 Jul 9. J Biol Chem. 2024. PMID: 38992437 Free PMC article.
• Cancer risks related to intellectual disabilities: A systematic review.
  Banda A, Naaldenberg J, Timen A, van Eeghen A, Leusink G, Cuypers M. Banda A, et al. Cancer Med. 2024 May;13(9):e7210. doi: 10.1002/cam4.7210. Cancer Med. 2024. PMID: 38686623 Free PMC article. Review.
• FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia.
  Ramanagoudr-Bhojappa R, Tryon R, Lach FP, Donovan FX, Maxwell R, Rosenberg A, MacMillan ML, Wagner JE, Auerbach AD, Smogorzewska A, Chandrasekharappa SC. Ramanagoudr-Bhojappa R, et al. Blood Adv. 2024 Feb 27;8(4):899-908. doi: 10.1182/bloodadvances.2023011888. Blood Adv. 2024. PMID: 38191666 Free PMC article.
• The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations.
  Hughes T, Rose AM. Hughes T, et al. Front Oncol. 2023 Dec 11;13:1278004. doi: 10.3389/fonc.2023.1278004. eCollection 2023. Front Oncol. 2023. PMID: 38146508 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Pagepress Publications

• Other Literature Sources

  • The Lens - Patent Citations